Abstract
81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.
| Original language | English |
|---|---|
| Pages (from-to) | 59-63 |
| Number of pages | 5 |
| Journal | New Trends in Experimental and Clinical Psychiatry |
| Volume | 14 |
| Issue number | 1 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Depressive
- Haloperidol dosages
- Negative-positive symptoms
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Mauri, M. C., Laini, V., Steinhilber, C. P. C., & Boscati, L. (1998). Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol. New Trends in Experimental and Clinical Psychiatry, 14(1), 59-63.